Trial reportVaccine2010
Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.
Trial report in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02276521 (Evaluation of Long-term Immunological Responses Following Reduced Dose Quadrivalent Human Papillomavirus), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Long-term Immunological Responses Following Reduced Dose Quadrivalent Human Papillomavirus (HPV) Vaccine Schedules: A Phase II/III Clinical Trial
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men.Vaccine · 2019Trial
- Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial.NPJ vaccines · 2025Article
- Helminth driven gut inflammation and microbial translocation associate with altered vaccine responses in rural Uganda.NPJ vaccines · 2025Article
- Article
- Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge.Human vaccines & immunotherapeutics · 2022Review
- Review
- Article
- Article
- Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial.The Journal of infectious diseases · 2016Article
- Article
- Alternative dosage schedules with HPV virus-like particle vaccines.Expert review of vaccines · 2014Review
- Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes.Vaccine · 2014Article
- Clinical trials of human papillomavirus vaccines and beyond.Nature reviews. Clinical oncology · 2013Review
- Article
- Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence.BMC research notes · 2011Article
- Prevention of cancer by prophylactic human papillomavirus vaccines.Current opinion in immunology · 2011Review
- HPV - immune response to infection and vaccination.Infectious agents and cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Human papillomavirus (HPV)-specific antibodies are proposed to be the correlate of protection afforded by HPV L1 virus-like particle (VLP) vaccines. Previous studies have characterized the systemic antibody response to immunization in terms of both the quantity and the ability to neutralize HPV. Here, we have adapted a generalized memory B cell ELISPOT to the HPV16 system and expanded the analysis of the systemic antibody response to include an avidity measurement of HPV L1 VLP-specific antibodies. We show the results of the memory B cell ELISPOT significantly correlated with IgG and neutralizing antibody titers, but not with the avidity measurement. This is the first comprehensive study to correlate a variety of humoral aspects potentially associated with protective immunity following vaccination with a HPV16 L1 VLP vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.